These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
341 related articles for article (PubMed ID: 27793942)
1. A Novel Aziridine-based Bruton's Tyrosine Kinase Inhibitor Induces Apoptosis Through Down-regulation of p65/RelA Phosphorylation on Serine 536 and ERK1/2 in Mantle Cell Lymphoma. Romanchikova N; Strods A; Strazdina J; Strumfs B; Trapencieris P Anticancer Res; 2016 Nov; 36(11):6133-6140. PubMed ID: 27793942 [TBL] [Abstract][Full Text] [Related]
2. The mTOR kinase inhibitor everolimus synergistically enhances the anti-tumor effect of the Bruton's tyrosine kinase (BTK) inhibitor PLS-123 on Mantle cell lymphoma. Li J; Wang X; Xie Y; Ying Z; Liu W; Ping L; Zhang C; Pan Z; Ding N; Song Y; Zhu J Int J Cancer; 2018 Jan; 142(1):202-213. PubMed ID: 28905990 [TBL] [Abstract][Full Text] [Related]
3. Targeting protein kinase C in mantle cell lymphoma. Rauert-Wunderlich H; Rudelius M; Ott G; Rosenwald A Br J Haematol; 2016 May; 173(3):394-403. PubMed ID: 26914495 [TBL] [Abstract][Full Text] [Related]
4. Bortezomib enhances the anti-cancer effect of the novel Bruton's tyrosine kinase inhibitor (BGB-3111) in mantle cell lymphoma expressing BTK. Wang X; Fei Y; Liu X; Zhang T; Li W; Jia X; Liu X; Qiu L; Qian Z; Zhou S; Ren X; Zhai Q; Meng B; Li L; Zhang H Aging (Albany NY); 2021 Sep; 13(17):21102-21121. PubMed ID: 34508613 [TBL] [Abstract][Full Text] [Related]
5. Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib. Sun B; Shah B; Fiskus W; Qi J; Rajapakshe K; Coarfa C; Li L; Devaraj SG; Sharma S; Zhang L; Wang ML; Saenz DT; Krieger S; Bradner JE; Bhalla KN Blood; 2015 Sep; 126(13):1565-74. PubMed ID: 26254443 [TBL] [Abstract][Full Text] [Related]
7. Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis. Cinar M; Hamedani F; Mo Z; Cinar B; Amin HM; Alkan S Leuk Res; 2013 Oct; 37(10):1271-7. PubMed ID: 23962569 [TBL] [Abstract][Full Text] [Related]
8. Discovery of pyrazolopyrimidine derivatives as potent BTK inhibitors with effective anticancer activity in MCL. Ran F; Liu Y; Liu M; Zhang D; Wang P; Dong J; Tang W; Zhao G Bioorg Chem; 2019 Aug; 89():102943. PubMed ID: 31031018 [TBL] [Abstract][Full Text] [Related]
9. ZCL-082, a boron-containing compound, induces apoptosis of non-Hodgkin's lymphoma via targeting p90 ribosomal S6 kinase 1/NF-κB signaling pathway. Ma C; Liu M; Zhang J; Cai H; Wu Y; Zhang Y; Ji Y; Shan H; Zou Z; Yang L; Liu L; Xu H; Lei H; Liu C; Zhou L; Cao Y; Zhou H; Wu Y Chem Biol Interact; 2022 Jan; 351():109770. PubMed ID: 34861246 [TBL] [Abstract][Full Text] [Related]
10. Design and synthesis of novel 1-substituted 3-(6-phenoxypyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine analogs as selective BTK inhibitors for the treatment of mantle cell lymphoma. Ran F; Liu Y; Yu S; Guo K; Tang W; Chen X; Zhao G Bioorg Chem; 2020 Jan; 94():103367. PubMed ID: 31685258 [TBL] [Abstract][Full Text] [Related]
11. Pleiotropic Action of Novel Bruton's Tyrosine Kinase Inhibitor BGB-3111 in Mantle Cell Lymphoma. Li CJ; Jiang C; Liu Y; Bell T; Ma W; Ye Y; Huang S; Guo H; Zhang H; Wang L; Wang J; Nomie K; Zhang L; Wang M Mol Cancer Ther; 2019 Feb; 18(2):267-277. PubMed ID: 30413649 [TBL] [Abstract][Full Text] [Related]
12. Design and synthesis of novel substituted benzyl pyrrolopyrimidine derivatives as selective BTK inhibitors for treating mantle cell lymphoma. Ran F; Liu Y; Chen X; Zhuo H; Xu C; Li Y; Duan X; Zhao G Bioorg Chem; 2021 Jul; 112():104968. PubMed ID: 34000704 [TBL] [Abstract][Full Text] [Related]
13. P276-00, a cyclin-dependent kinase inhibitor, modulates cell cycle and induces apoptosis in vitro and in vivo in mantle cell lymphoma cell lines. Shirsath NP; Manohar SM; Joshi KS Mol Cancer; 2012 Oct; 11():77. PubMed ID: 23075291 [TBL] [Abstract][Full Text] [Related]
14. Bruton's tyrosine kinase inhibitors in B-cell lymphoma: current experience and future perspectives. Seiler T; Dreyling M Expert Opin Investig Drugs; 2017 Aug; 26(8):909-915. PubMed ID: 28661188 [TBL] [Abstract][Full Text] [Related]
15. The synergistic effect of BCR signaling inhibitors combined with an HDAC inhibitor on cell death in a mantle cell lymphoma cell line. Hagiwara K; Kunishima S; Iida H; Miyata Y; Naoe T; Nagai H Apoptosis; 2015 Jul; 20(7):975-85. PubMed ID: 25835755 [TBL] [Abstract][Full Text] [Related]
16. Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma. Peponi E; Drakos E; Reyes G; Leventaki V; Rassidakis GZ; Medeiros LJ Am J Pathol; 2006 Dec; 169(6):2171-80. PubMed ID: 17148679 [TBL] [Abstract][Full Text] [Related]
17. Transcription and translation are primary targets of Pim kinase inhibitor SGI-1776 in mantle cell lymphoma. Yang Q; Chen LS; Neelapu SS; Miranda RN; Medeiros LJ; Gandhi V Blood; 2012 Oct; 120(17):3491-500. PubMed ID: 22955922 [TBL] [Abstract][Full Text] [Related]
18. Ibrutinib for the treatment of mantle cell lymphoma. Shah N; Hutchinson C; Rule S Expert Rev Hematol; 2014 Oct; 7(5):521-31. PubMed ID: 25158606 [TBL] [Abstract][Full Text] [Related]
19. Concurrent inhibition of PI3K and mTORC1/mTORC2 overcomes resistance to rapamycin induced apoptosis by down-regulation of Mcl-1 in mantle cell lymphoma. Müller A; Zang C; Chumduri C; Dörken B; Daniel PT; Scholz CW Int J Cancer; 2013 Oct; 133(8):1813-24. PubMed ID: 23580240 [TBL] [Abstract][Full Text] [Related]